A time-resolved fluorescence immunoassay for the determination of a novel respiratory therapeutic agent, AR-C68397XX (Viozan) in human plasma.
A dissociation-enhanced lathanide fluorescence immunoassay (DELFIA) method has been developed for the determination of AR-C68397XX, a novel respiratory therapeutic agent, in human plasma. The method is a 'direct' immunoassay and provides an alternative to the solid phase extraction RIA described in a previous publication, which employs the same specific antiserum. The DELFIA method is suitable for the determination of the analyte at pg ml(-1) concentrations. The non-isotopic label was prepared by complexation of a DTPA derivative of AR-C68397XX with free europium cation (Eu3+). Plasma samples were diluted at least 5-fold prior to analysis to eliminate matrix interference. The calibration range is 10-2000 pg ml(-1), and the LOQ of the method is 50 pg ml(-1) using 50 microl of diluted human plasma sample.
Willson
V J
VJ
Department of Drug Development Metabolism and Bioanalysis, AstraZeneca R&D Charnwood, Loughborough, Leics., UK. viv.willson@astrazeneca.com
Lockley
W J
WJ
Mather
A
A
Singh
J
J
Gilbert
C M
CM
Bayliss
M A
MA
Wilkinson
D
D
D000318:Adrenergic beta-Agonists / Q000097:blood* / Q000627:therapeutic use; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008173:Lung Diseases, Obstructive / Q000188:drug therapy; D015203:Reproducibility of Results; D013844:Thiazoles / Q000097:blood* / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D013844:Thiazoles; C116267:sibenadet